Pfizer [PFIZER] vs Gland Pharma [GLAND] Detailed Stock Comparison
Pfizer
NSE
Loading...
Gland Pharma
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Pfizer wins in 11 metrics, Gland Pharma wins in 9 metrics, with 0 ties. Pfizer appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Pfizer | Gland Pharma | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 29.68 | 41.10 | Pfizer |
| Price-to-Book Ratio | 5.69 | 3.47 | Gland Pharma |
| Debt-to-Equity Ratio | 2.57 | 3.43 | Pfizer |
| PEG Ratio | 1.09 | 0.82 | Gland Pharma |
| EV/EBITDA | 28.90 | 21.83 | Gland Pharma |
| Profit Margin (TTM) | 34.83% | 13.47% | Pfizer |
| Operating Margin (TTM) | 32.44% | 17.71% | Pfizer |
| EBITDA Margin (TTM) | 32.44% | 17.71% | Pfizer |
| Return on Equity | 18.20% | 7.63% | Pfizer |
| Return on Assets (TTM) | 15.63% | 6.22% | Pfizer |
| Free Cash Flow (TTM) | $6.32B | $5.21B | Pfizer |
| Dividend Yield | 1.27% | 1.95% | Gland Pharma |
| 1-Year Return | -14.99% | 1.79% | Gland Pharma |
| Price-to-Sales Ratio (TTM) | 10.35 | 5.54 | Gland Pharma |
| Enterprise Value | $213.39B | $291.18B | Gland Pharma |
| EV/Revenue Ratio | 9.19 | 5.09 | Gland Pharma |
| Gross Profit Margin (TTM) | 64.97% | 65.39% | Gland Pharma |
| Revenue per Share (TTM) | $507 | $347 | Pfizer |
| Earnings per Share (Diluted) | $176.89 | $46.84 | Pfizer |
| Beta (Stock Volatility) | 0.13 | 0.40 | Pfizer |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Pfizer vs Gland Pharma Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Pfizer | -0.23% | -9.04% | -2.29% | -7.69% | 27.29% | -2.85% |
| Gland Pharma | -0.81% | -4.39% | -10.97% | 18.58% | 20.52% | 3.39% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Pfizer | -14.99% | 21.06% | 7.99% | 122.80% | 366.27% | 545.63% |
| Gland Pharma | 1.79% | -27.07% | 2.86% | 2.86% | 2.86% | 2.86% |
Performance & Financial Health Analysis: Pfizer vs Gland Pharma
| Metric | PFIZER | GLAND |
|---|---|---|
| Market Information | ||
| Market Cap | ₹240.18B | ₹317.16B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 113,572 | 205,599 |
| 90 Day Avg. Volume | 50,263 | 413,190 |
| Last Close | ₹5,156.00 | ₹1,871.50 |
| 52 Week Range | ₹3,701.00 - ₹6,451.15 | ₹1,277.80 - ₹2,131.00 |
| % from 52W High | -20.08% | -12.18% |
| All-Time High | ₹6,451.15 (Sep 02, 2024) | ₹4,350.00 (Aug 09, 2021) |
| % from All-Time High | -20.08% | -56.98% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.07% | 0.07% |
| Quarterly Earnings Growth | 0.27% | 0.50% |
| Financial Health | ||
| Profit Margin (TTM) | 0.35% | 0.13% |
| Operating Margin (TTM) | 0.32% | 0.18% |
| Return on Equity (TTM) | 0.18% | 0.08% |
| Debt to Equity (MRQ) | 2.57 | 3.43 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹921.88 | ₹555.41 |
| Cash per Share (MRQ) | ₹608.26 | ₹179.19 |
| Operating Cash Flow (TTM) | ₹9.08B | ₹7.50B |
| Levered Free Cash Flow (TTM) | ₹7.68B | ₹6.99B |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.27% | 1.95% |
| Last 12-Month Dividend | ₹70.00 | ₹38.00 |
Valuation & Enterprise Metrics Analysis: Pfizer vs Gland Pharma
| Metric | PFIZER | GLAND |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 29.68 | 41.10 |
| Forward P/E | 31.36 | 29.61 |
| PEG Ratio | 1.09 | 0.82 |
| Price to Sales (TTM) | 10.35 | 5.54 |
| Price to Book (MRQ) | 5.69 | 3.47 |
| Market Capitalization | ||
| Market Capitalization | ₹240.18B | ₹317.16B |
| Enterprise Value | ₹213.39B | ₹291.18B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 9.19 | 5.09 |
| Enterprise to EBITDA | 28.90 | 21.83 |
| Risk & Other Metrics | ||
| Beta | 0.13 | 0.40 |
| Book Value per Share (MRQ) | ₹921.88 | ₹555.41 |
Financial Statements Comparison: Pfizer vs Gland Pharma
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PFIZER | GLAND |
|---|---|---|
| Revenue/Sales | ₹6.03B | ₹15.06B |
| Cost of Goods Sold | ₹2.11B | ₹5.21B |
| Gross Profit | ₹3.92B | ₹9.84B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹1.96B | ₹2.67B |
| EBITDA | ₹2.77B | ₹4.25B |
| Pre-Tax Income | ₹2.60B | ₹3.13B |
| Income Tax | ₹677.80M | ₹972.59M |
| Net Income (Profit) | ₹1.92B | ₹2.15B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PFIZER | GLAND |
|---|---|---|
| Cash & Equivalents | ₹4.95B | ₹25.56B |
| Total Current Assets | ₹35.13B | ₹67.83B |
| Total Current Liabilities | ₹5.70B | ₹15.65B |
| Long-Term Debt | ₹676.20M | ₹1.07B |
| Total Shareholders Equity | ₹42.17B | ₹91.51B |
| Retained Earnings | ₹24.36B | ₹71.57B |
| Property, Plant & Equipment | ₹1.72B | ₹3.59B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PFIZER | GLAND |
|---|---|---|
| Operating Cash Flow | N/A | ₹2.07B |
| Capital Expenditures | N/A | ₹-659.37M |
| Free Cash Flow | N/A | ₹126.04M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PFIZER | GLAND |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 113,572 | 205,599 |
| Average Daily Volume (90 Day) | 50,263 | 413,190 |
| Shares Outstanding | 45.75M | 164.76M |
| Float Shares | 15.12M | 73.18M |
| % Held by Insiders | 0.67% | 0.52% |
| % Held by Institutions | 0.17% | 0.37% |
Dividend Analysis & Yield Comparison: Pfizer vs Gland Pharma
| Metric | PFIZER | GLAND |
|---|---|---|
| Last 12-Month Dividend | ₹70.00 | ₹38.00 |
| Last 12-Month Dividend Yield | 1.27% | 1.95% |
| 3-Year Avg Annual Dividend | ₹46.67 | ₹12.67 |
| 3-Year Avg Dividend Yield | 0.58% | 1.00% |
| 3-Year Total Dividends | ₹140.00 | ₹38.00 |
| Ex-Dividend Date | Jul 09, 2025 | Aug 14, 2025 |